Nova matches university research with global commercialization opportunities.

An AI platform for research commercialization, developed with Zima Labs. Nova assesses a patent's licensing potential against market evidence and finds the licensees that fit, in minutes, not weeks.

What Nova does

Qualified leads and personalized pitch decks, from one question.

Nova runs patent analysis and IP evaluation across a university's entire portfolio, scores each asset for commercialization readiness against the competition, shortlists licensees and investors, and puts together marketing materials tailored to each prospect.

  1. Ask

    Ask in plain language, from a field or a single invention.

    Which inventions help CAR-T cells survive longer in patients, and who would license them?

    Invention Immuno-oncology · CAR-T
  2. Evaluate

    Licensable or not, on what evidence, against whom.

    Licensing · Evaluate

    Selective expansion switch for engineered immune cells

    Licensee interest 88/100 · High
    Competitive intensity High
    5 franchises4 trials3 public statements
  3. Match

    To whom, ranked with reasons, from deals and pipelines on the record.

    Licensing · Lead gen

    Candidate licensees

    StrongComplementary fit3

    1. 1Global pharma, CAR-T franchise91/100 fitOwns two approved CAR-T products. Actively scouting persistence enhancers.
    2. 2Biotech, cell-therapy platform85/100 fitPrioritizing durability for its CAR-T portfolio. Complementary, not competing.
    3. 3Large pharma, next-gen cell therapy72/100 fit
  4. Outreach

    An email and a deck, drafted per licensee, ready to send.

    Cover email

    Helping CAR-T cells survive longer in patients

    Proposal deck

    A built-in switch that makes CAR-T cells multiply and persist.

    Draft in Gmail

Developed with Zima Labs

Nova is powered by Zima Labs, the unified intelligence above an organization's data.

Ready to transform your legacy data into insight that acts and edge that compounds?